Insights

Introduction

The first Joint Clinical Assessment (JCA) under the EU HTA Regulation has now been published, marking the transition from a regulatory concept to an operational reality.

This inaugural report, focused on tovorafenib (OJEMDA) in paediatric low-grade glioma, provides the first tangible insight into how the EU HTA framework will perform in practice and what it will require from pharmaceutical companies.

Assessment overview

The assessment was structured around eight PICOs, reflecting the EU ambition to capture multiple clinical settings and comparators across Member States.

However, only one PICO could be meaningfully informed by comparative evidence, immediately highlighting the gap between available clinical data and HTA expectations.

Key findings

Most PICOs could not be assessed due to the absence of comparator data, limiting the ability to draw conclusions across relevant clinical scenarios.

Where comparative analysis was performed, it relied on unanchored indirect comparison methods (MAIC) applied to a single subpopulation, based on non-comparative clinical evidence.

Main limitations

The assessment is characterised by a high level of uncertainty, driven by small sample sizes, reliance on single-arm studies, and methodological constraints inherent to indirect comparisons.

In addition, the absence of overall survival data and the limited robustness of key endpoints further restrict the interpretability of results.

Importantly, the report explicitly states that findings should not be interpreted as causal, reinforcing the limitations of the available evidence base.

Strategic implications

This first JCA sends a clear signal for future EU submissions.

While indirect comparisons may be accepted in the absence of head-to-head evidence, they are subject to rigorous methodological scrutiny and full transparency on uncertainty.

More importantly, this assessment confirms that early evidence planning aligned with HTA requirements is becoming critical, particularly in areas where randomised evidence may be limited.

Conclusion

This first publication is more than a single assessment — it is a signal document for the future of EU HTA.

It confirms that EU HTA is now operational, and that expectations on clinical evidence are becoming increasingly structured and transparent.

RPN supports companies in navigating the evolving EU HTA landscape, from early evidence strategy to JCA readiness, ensuring alignment between regulatory and market access requirements and strengthening the robustness of submissions across Europe.